{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:09:17Z","timestamp":1793725757382,"version":"4.6.1"},"reference-count":323,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AGIHO"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00277-016-2711-1","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T09:43:30Z","timestamp":1466847810000},"page":"1435-1455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016"],"prefix":"10.1007","volume":"95","author":[{"name":"on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO\/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Ullmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schmidt-Hieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J.","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kiehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Neuburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Silling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg Janne","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Maschmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"issue":"14","key":"2711_CR1","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/archinte.162.14.1558","volume":"162","author":"IA Tabbara","year":"2002","unstructured":"Tabbara IA et al (2002) Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med 162(14):1558\u20131566","journal-title":"Arch Intern Med"},{"issue":"3","key":"2711_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.seminhematol.2009.03.005","volume":"46","author":"JW Hiemenz","year":"2009","unstructured":"Hiemenz JW (2009) Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol 46(3):289\u2013312","journal-title":"Semin Hematol"},{"issue":"Suppl 2","key":"2711_CR3","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1007\/s00277-003-0772-4","volume":"82","author":"H Einsele","year":"2003","unstructured":"Einsele H et al (2003) Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies\u2014guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S175\u2013S185","journal-title":"Ann Hematol"},{"key":"2711_CR4","doi-asserted-by":"crossref","unstructured":"Ullmann AJ et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 18(Suppl 7):1\u20138","DOI":"10.1111\/1469-0691.12037"},{"issue":"7","key":"2711_CR5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1086\/501661","volume":"20","author":"M Cornet","year":"1999","unstructured":"Cornet M et al (1999) Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 20(7):508\u2013513","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"2711_CR6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1086\/503435","volume":"193","author":"T Eckmanns","year":"2006","unstructured":"Eckmanns T, Ruden H, Gastmeier P (2006) The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 193(10):1408\u20131418","journal-title":"J Infect Dis"},{"issue":"4","key":"2711_CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.1054","volume":"66","author":"I Oren","year":"2001","unstructured":"Oren I et al (2001) Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 66(4):257\u2013262","journal-title":"Am J Hematol"},{"issue":"3","key":"2711_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/152581603322023034","volume":"12","author":"WH Kruger","year":"2003","unstructured":"Kruger WH et al (2003) Effective protection of allogeneic stem cell recipients against Aspergillosis by HEPA air filtration during a period of construction\u2014a prospective survey. J Hematother Stem Cell Res 12(3):301\u2013307","journal-title":"J Hematother Stem Cell Res"},{"issue":"11\u201312","key":"2711_CR9","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/jocn.12286","volume":"23","author":"S Vokurka","year":"2014","unstructured":"Vokurka S et al (2014) The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study. J Clin Nurs 23(11\u201312):1648\u20131652","journal-title":"J Clin Nurs"},{"issue":"2","key":"2711_CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhin.2003.10.011","volume":"56","author":"H Humphreys","year":"2004","unstructured":"Humphreys H (2004) Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence? J Hosp Infect 56(2):93\u2013100, quiz 163","journal-title":"J Hosp Infect"},{"issue":"5","key":"2711_CR11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.bmt.1705040","volume":"36","author":"B Hayes-Lattin","year":"2005","unstructured":"Hayes-Lattin B, Leis JF, Maziarz RT (2005) Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant 36(5):373\u2013381","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2711_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.bmt.1704380","volume":"33","author":"S McCann","year":"2004","unstructured":"McCann S et al (2004) Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 33(5):519\u2013529","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2711_CR13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/infdis\/165.6.987","volume":"165","author":"RD Harrington","year":"1992","unstructured":"Harrington RD et al (1992) An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 165(6):987\u2013993","journal-title":"J Infect Dis"},{"issue":"3","key":"2711_CR14","first-page":"393","volume":"16","author":"E Whimbey","year":"1995","unstructured":"Whimbey E et al (1995) Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 16(3):393\u2013399","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2711_CR15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1128\/JCM.39.2.801-803.2001","volume":"39","author":"GS Taylor","year":"2001","unstructured":"Taylor GS, Vipond IB, Caul EO (2001) Molecular epidemiology of outbreak of respiratory syncytial virus within bone marrow transplantation unit. J Clin Microbiol 39(2):801\u2013803","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2711_CR16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1079\/PNS200078","volume":"60","author":"EC McWilliam Leitch","year":"2001","unstructured":"McWilliam Leitch EC et al (2001) Dietary effects on the microbiological safety of food. Proc Nutr Soc 60(2):247\u2013255","journal-title":"Proc Nutr Soc"},{"issue":"11","key":"2711_CR17","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.bbmt.2014.06.034","volume":"20","author":"NM Boyle","year":"2014","unstructured":"Boyle NM et al (2014) Bacterial foodborne infections after hematopoietic cell transplantation. Biol Blood Marrow Transplant 20(11):1856\u20131861","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2711_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhin.2009.04.019","volume":"73","author":"B Allegranzi","year":"2009","unstructured":"Allegranzi B, Pittet D (2009) Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect 73(4):305\u2013315","journal-title":"J Hosp Infect"},{"key":"2711_CR19","unstructured":"CE1-7 (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 49(RR-10)1\u2013125"},{"key":"2711_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2334-7-45","volume":"7","author":"G Daeschlein","year":"2007","unstructured":"Daeschlein G et al (2007) Hygienic safety of reusable tap water filters (Germlyser) with an operating time of 4 or 8 weeks in a haematological oncology transplantation unit. BMC Infect Dis 7:45","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2711_CR21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/1469-0691.12299","volume":"20","author":"ZY Zhou","year":"2014","unstructured":"Zhou ZY et al (2014) Removal of waterborne pathogens from liver transplant unit water taps in prevention of healthcare-associated infections: a proposal for a cost-effective, proactive infection control strategy. Clin Microbiol Infect 20(4):310\u2013314","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2711_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1399-3062.2009.00459.x","volume":"12","author":"JS Cervia","year":"2010","unstructured":"Cervia JS et al (2010) Point-of-use water filtration reduces healthcare-associated infections in bone marrow transplant recipients. Transpl Infect Dis 12(3):238\u2013241","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"2711_CR23","first-page":"543","volume":"4","author":"SM Kelsey","year":"1989","unstructured":"Kelsey SM, Newland AC (1989) Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 4(5):543\u2013546","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2711_CR24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bmt.2010.94","volume":"45","author":"M Hamadani","year":"2010","unstructured":"Hamadani M et al (2010) How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 45(8):1259\u20131268","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2711_CR25","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","volume":"122","author":"M Schmidt-Hieber","year":"2013","unstructured":"Schmidt-Hieber M et al (2013) CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 122(19):3359\u20133364","journal-title":"Blood"},{"issue":"Suppl 1","key":"2711_CR26","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/clinids\/21.Supplement_1.S114","volume":"21","author":"JA Stewart","year":"1995","unstructured":"Stewart JA et al (1995) Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 21(Suppl 1):S114\u2013S120","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2711_CR27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.1999.17.1.394","volume":"17","author":"R Liang","year":"1999","unstructured":"Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17(1):394\u2013398","journal-title":"J Clin Oncol"},{"issue":"9","key":"2711_CR28","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","volume":"15","author":"SP Hammond","year":"2009","unstructured":"Hammond SP et al (2009) Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1049\u20131059","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2711_CR29","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","volume":"113","author":"R Liang","year":"2009","unstructured":"Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113(14):3147\u20133153","journal-title":"Blood"},{"issue":"9","key":"2711_CR30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1704457","volume":"33","author":"A Knoll","year":"2004","unstructured":"Knoll A et al (2004) Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33(9):925\u2013929","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2711_CR31","doi-asserted-by":"crossref","first-page":"O694","DOI":"10.1111\/1469-0691.12611","volume":"20","author":"M Mikulska","year":"2014","unstructured":"Mikulska M et al (2014) Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 20(10):O694\u2013O701","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"2711_CR32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1665-2681(19)30778-1","volume":"14","author":"M Pompili","year":"2015","unstructured":"Pompili M et al (2015) Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Ann Hepatol 14(2):168\u2013174","journal-title":"Ann Hepatol"},{"key":"2711_CR33","doi-asserted-by":"crossref","unstructured":"Takahata M et al. (2014) Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis 16(5):797\u2013801","DOI":"10.1111\/tid.12283"},{"issue":"6","key":"2711_CR34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2008.03.003","volume":"48","author":"R Peffault de Latour","year":"2008","unstructured":"Peffault de Latour R et al (2008) Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol 48(6):1008\u20131017","journal-title":"J Hepatol"},{"issue":"5","key":"2711_CR35","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2003-06-2145","volume":"103","author":"R Peffault de Latour","year":"2004","unstructured":"de Latour Peffault R (2004) Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103(5):1618\u20131624","journal-title":"Blood"},{"issue":"1","key":"2711_CR36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007890-198907000-00016","volume":"48","author":"A Locasciulli","year":"1989","unstructured":"Locasciulli A et al (1989) Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 48(1):68\u201372","journal-title":"Transplantation"},{"issue":"5","key":"2711_CR37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","volume":"84","author":"JH Lee","year":"2005","unstructured":"Lee JH et al (2005) Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan\u2009+\u2009cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84(5):321\u2013330","journal-title":"Ann Hematol"},{"issue":"4","key":"2711_CR38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/QCO.0000000000000076","volume":"27","author":"AA Eijk van der","year":"2014","unstructured":"van der Eijk AA et al (2014) Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 27(4):309\u2013315","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"2711_CR39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1182\/blood-2013-03-492363","volume":"122","author":"J Versluis","year":"2013","unstructured":"Versluis J et al (2013) Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood 122(6):1079\u20131086","journal-title":"Blood"},{"issue":"5","key":"2711_CR40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2008.165571","volume":"58","author":"P Coutre le","year":"2009","unstructured":"le Coutre P et al (2009) Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 58(5):699\u2013702","journal-title":"Gut"},{"key":"2711_CR41","doi-asserted-by":"crossref","unstructured":"Bettinger D et al. (2014) Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease. Ann Hematol 94(2):359\u2013360","DOI":"10.1007\/s00277-014-2163-4"},{"issue":"3","key":"2711_CR42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2249.2010.04312.x","volume":"163","author":"G Hutter","year":"2011","unstructured":"Hutter G, Zaia JA (2011) Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25\u00a0years. Clin Exp Immunol 163(3):284\u2013295","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"2711_CR43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter G et al (2009) Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med 360(7):692\u2013698","journal-title":"N Engl J Med"},{"issue":"25","key":"2711_CR44","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1056\/NEJMc1412279","volume":"371","author":"G Hutter","year":"2014","unstructured":"Hutter G (2014) More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32\/delta32 mutation. N Engl J Med 371(25):2437\u20132438","journal-title":"N Engl J Med"},{"issue":"11","key":"2711_CR45","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/infdis\/jit086","volume":"207","author":"TJ Henrich","year":"2013","unstructured":"Henrich TJ et al (2013) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 207(11):1694\u20131702","journal-title":"J Infect Dis"},{"issue":"10","key":"2711_CR46","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.bmt.1704941","volume":"35","author":"WY Au","year":"2005","unstructured":"Au WY, Lie AK, Cheng VC (2005) VDRL screening and haemopoietic stem cell transplantation. Bone Marrow Transplant 35(10):1027\u20131028","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2711_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1086\/426447","volume":"40","author":"R Martino","year":"2005","unstructured":"Martino R et al (2005) Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis 40(1):67\u201378","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2711_CR48","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1086\/595709","volume":"48","author":"H Fricker-Hidalgo","year":"2009","unstructured":"Fricker-Hidalgo H et al (2009) Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin Infect Dis 48(2):e9\u2013e15","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2711_CR49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jinf.2014.02.019","volume":"69","author":"YM Lee","year":"2014","unstructured":"Lee YM et al (2014) A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. J Infect 69(2):165\u2013173","journal-title":"J Infect"},{"issue":"5","key":"2711_CR50","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","volume":"146","author":"D Menzies","year":"2007","unstructured":"Menzies D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146(5):340\u2013354","journal-title":"Ann Intern Med"},{"issue":"1","key":"2711_CR51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1399-3062.2012.00765.x","volume":"15","author":"SM Moon","year":"2013","unstructured":"Moon SM et al (2013) Comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis 15(1):104\u2013109","journal-title":"Transpl Infect Dis"},{"key":"2711_CR52","doi-asserted-by":"crossref","unstructured":"Biehl LM et al (2014) Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients\u2014review of the literature from a clinical perspective. Crit Rev Microbiol 42(1):1\u201316","DOI":"10.3109\/1040841X.2013.875515"},{"issue":"6","key":"2711_CR53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s15010-012-0269-y","volume":"40","author":"BJ Liss","year":"2012","unstructured":"Liss BJ et al (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40(6):613\u2013619","journal-title":"Infection"},{"issue":"4","key":"2711_CR54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.bmt.1705912","volume":"41","author":"A Zirakzadeh","year":"2008","unstructured":"Zirakzadeh A et al (2008) Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41(4):385\u2013392","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2711_CR55","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1705530","volume":"38","author":"ER Dubberke","year":"2006","unstructured":"Dubberke ER et al (2006) Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 38(12):813\u2013819","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2711_CR56","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/502305","volume":"25","author":"M Thouverez","year":"2004","unstructured":"Thouverez M, Talon D, Bertrand X (2004) Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. Infect Control Hosp Epidemiol 25(10):838\u2013841","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"2711_CR57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1086\/502575","volume":"26","author":"S Blot","year":"2005","unstructured":"Blot S et al (2005) Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol 26(6):575\u2013579","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"2711_CR58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.bmt.1704414","volume":"33","author":"P Frere","year":"2004","unstructured":"Frere P et al (2004) Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant 33(7):745\u2013749","journal-title":"Bone Marrow Transplant"},{"key":"2711_CR59","doi-asserted-by":"crossref","unstructured":"Mikulska M (2015) How to manage infections caused by antibiotic resistant gram-negative bacteria - EBMT Educational Meeting from the severe aplastic anaemia and infectious diseases working parties, Naples, Italy, 2014. Curr Drug Targets","DOI":"10.2174\/1389450116666150223162138"},{"issue":"6","key":"2711_CR60","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MOH.0000000000000088","volume":"21","author":"M Mikulska","year":"2014","unstructured":"Mikulska M, Del Bono V, Viscoli C (2014) Bacterial infections in hematopoietic stem cell transplantation recipients. Curr Opin Hematol 21(6):451\u2013458","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"2711_CR61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11899-007-0014-2","volume":"2","author":"SP Hammond","year":"2007","unstructured":"Hammond SP, Baden LR (2007) Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Curr Hematol Malig Rep 2(2):97\u2013103","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"2711_CR62","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve G et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977\u2013987","journal-title":"N Engl J Med"},{"key":"2711_CR63","first-page":"CD004386","volume":"1","author":"A Gafter-Gvili","year":"2012","unstructured":"Gafter-Gvili A et al (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2711_CR64","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","volume":"353","author":"M Cullen","year":"2005","unstructured":"Cullen M et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353(10):988\u2013998","journal-title":"N Engl J Med"},{"issue":"8","key":"2711_CR65","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cncr.22205","volume":"107","author":"L Leibovici","year":"2006","unstructured":"Leibovici L et al (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107(8):1743\u20131751","journal-title":"Cancer"},{"issue":"22","key":"2711_CR66","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2003.01.234","volume":"21","author":"M Cruciani","year":"2003","unstructured":"Cruciani M et al (2003) Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 21(22):4127\u20134137","journal-title":"J Clin Oncol"},{"issue":"1","key":"2711_CR67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jinf.2014.02.013","volume":"69","author":"S Kimura","year":"2014","unstructured":"Kimura S et al (2014) Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect 69(1):13\u201325","journal-title":"J Infect"},{"issue":"1\u20132","key":"2711_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428199709109152","volume":"26","author":"V Roy","year":"1997","unstructured":"Roy V, Ochs L, Weisdorf D (1997) Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 26(1\u20132):1\u201315","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2711_CR69","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood.V86.10.3979.bloodjournal86103979","volume":"86","author":"L Ochs","year":"1995","unstructured":"Ochs L et al (1995) Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 86(10):3979\u20133986","journal-title":"Blood"},{"issue":"12","key":"2711_CR70","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood.V95.12.3683","volume":"95","author":"S Kulkarni","year":"2000","unstructured":"Kulkarni S et al (2000) Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95(12):3683\u20133686","journal-title":"Blood"},{"issue":"3","key":"2711_CR71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10156-003-0252-8","volume":"9","author":"H Mitsui","year":"2003","unstructured":"Mitsui H et al (2003) Analysis of sepsis in allogeneic bone marrow transplant recipients: a single-center study. J Infect Chemother 9(3):238\u2013242","journal-title":"J Infect Chemother"},{"issue":"7","key":"2711_CR72","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2014-02-554725","volume":"124","author":"Y Taur","year":"2014","unstructured":"Taur Y et al (2014) The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124(7):1174\u20131182","journal-title":"Blood"},{"issue":"7","key":"2711_CR73","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/cis580","volume":"55","author":"Y Taur","year":"2012","unstructured":"Taur Y et al (2012) Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55(7):905\u2013914","journal-title":"Clin Infect Dis"},{"issue":"339","key":"2711_CR74","doi-asserted-by":"crossref","first-page":"339ra71","DOI":"10.1126\/scitranslmed.aaf2311","volume":"8","author":"Y Shono","year":"2016","unstructured":"Shono Y et al (2016) Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 8(339):339ra71","journal-title":"Sci Transl Med"},{"issue":"10","key":"2711_CR75","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","volume":"36","author":"N Castro De","year":"2005","unstructured":"De Castro N et al (2005) Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 36(10):879\u2013883","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2711_CR76","first-page":"267","volume":"10","author":"IZ Tuan","year":"1992","unstructured":"Tuan IZ, Dennison D, Weisdorf DJ (1992) Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 10(3):267\u2013272","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2711_CR77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/bmt.2015.316","volume":"51","author":"KM Williams","year":"2016","unstructured":"Williams KM et al (2016) The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant 51(4):573\u2013580","journal-title":"Bone Marrow Transplant"},{"issue":"9148","key":"2711_CR78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(98)07204-3","volume":"353","author":"MM Schneider","year":"1999","unstructured":"Schneider MM et al (1999) Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 353(9148):201\u2013203","journal-title":"Lancet"},{"issue":"26","key":"2711_CR79","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM198706253162604","volume":"316","author":"WT Hughes","year":"1987","unstructured":"Hughes WT et al (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316(26):1627\u20131632","journal-title":"N Engl J Med"},{"issue":"26","key":"2711_CR80","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM197712292972602","volume":"297","author":"WT Hughes","year":"1977","unstructured":"Hughes WT et al (1977) Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 297(26):1419\u20131426","journal-title":"N Engl J Med"},{"issue":"9","key":"2711_CR81","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1128\/AAC.35.9.1705","volume":"35","author":"DS Stein","year":"1991","unstructured":"Stein DS et al (1991) Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 35(9):1705\u20131709","journal-title":"Antimicrob Agents Chemother"},{"key":"2711_CR82","first-page":"CD005590","volume":"10","author":"A Stern","year":"2014","unstructured":"Stern A et al (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD005590","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2711_CR83","first-page":"1057","volume":"17","author":"O Lyytikainen","year":"1996","unstructured":"Lyytikainen O et al (1996) Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplant 17(6):1057\u20131059","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2711_CR84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1083-8791(00)70050-4","volume":"6","author":"MJ Vasconcelles","year":"2000","unstructured":"Vasconcelles MJ et al (2000) Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant 6(1):35\u201343","journal-title":"Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant"},{"key":"2711_CR85","first-page":"CD005590","volume":"3","author":"H Green","year":"2007","unstructured":"Green H et al (2007) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 3:CD005590","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2711_CR86","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1702004","volume":"24","author":"C Colby","year":"1999","unstructured":"Colby C et al (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim\/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24(8):897\u2013902","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2711_CR87","first-page":"403","volume":"11","author":"H Link","year":"1993","unstructured":"Link H et al (1993) Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 11(5):403\u2013406","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2711_CR88","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1399-3062.2002.t01-1-00008.x","volume":"4","author":"TK Marras","year":"2002","unstructured":"Marras TK et al (2002) Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis 4(2):66\u201374","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"2711_CR89","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/314893","volume":"180","author":"C Chan","year":"1999","unstructured":"Chan C et al (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180(2):369\u2013376","journal-title":"J Infect Dis"},{"issue":"6","key":"2711_CR90","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1086\/313509","volume":"29","author":"JP Souza","year":"1999","unstructured":"Souza JP et al (1999) High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 29(6):1467\u20131471","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2711_CR91","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1399-3062.2008.00321.x","volume":"10","author":"A Tomonari","year":"2008","unstructured":"Tomonari A et al (2008) No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation. Transpl Infect Dis 10(5):303\u2013307","journal-title":"Transpl Infect Dis"},{"issue":"21","key":"2711_CR92","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","volume":"328","author":"W Hughes","year":"1993","unstructured":"Hughes W et al (1993) Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 328(21):1521\u20131527","journal-title":"N Engl J Med"},{"issue":"26","key":"2711_CR93","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","volume":"339","author":"WM El-Sadr","year":"1998","unstructured":"El-Sadr WM et al (1998) Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 339(26):1889\u20131895","journal-title":"N Engl J Med"},{"issue":"8","key":"2711_CR94","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis DP et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091\u20131100","journal-title":"Clin Infect Dis"},{"key":"2711_CR95","doi-asserted-by":"crossref","unstructured":"Martino R et al (2002) Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 116(2):475\u2013482","DOI":"10.1046\/j.1365-2141.2002.03259.x"},{"issue":"12","key":"2711_CR96","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.micinf.2009.07.002","volume":"11","author":"V Balloy","year":"2009","unstructured":"Balloy V, Chignard M (2009) The innate immune response to Aspergillus fumigatus. Microbes Infect 11(12):919\u2013927","journal-title":"Microbes Infect"},{"issue":"4","key":"2711_CR97","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1399-3062.2010.00497.x","volume":"12","author":"P Zhang","year":"2010","unstructured":"Zhang P et al (2010) Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience. Transpl Infect Dis 12(4):316\u2013321","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"2711_CR98","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/591969","volume":"47","author":"C Garcia-Vidal","year":"2008","unstructured":"Garcia-Vidal C et al (2008) Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 47(8):1041\u20131050","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2711_CR99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1399-3062.2007.00219.x","volume":"9","author":"MJ Post","year":"2007","unstructured":"Post MJ et al (2007) Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 9(3):189\u2013195","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"2711_CR100","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/myc.12081","volume":"56","author":"RE Lewis","year":"2013","unstructured":"Lewis RE et al (2013) Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56(6):638\u2013645","journal-title":"Mycoses"},{"issue":"2","key":"2711_CR101","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1399-3062.2007.00264.x","volume":"10","author":"J Sinko","year":"2008","unstructured":"Sinko J et al (2008) Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis 10(2):106\u2013109","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"2711_CR102","first-page":"986","volume":"91","author":"G Chamilos","year":"2006","unstructured":"Chamilos G et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989\u20132003). Haematologica 91(7):986\u2013989","journal-title":"Haematologica"},{"issue":"7","key":"2711_CR103","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/500934","volume":"42","author":"C Cordonnier","year":"2006","unstructured":"Cordonnier C et al (2006) Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 42(7):955\u2013963","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2711_CR104","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","volume":"95","author":"C Cordonnier","year":"2010","unstructured":"Cordonnier C et al (2010) Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 95(10):1762\u20131768","journal-title":"Haematologica"},{"issue":"10","key":"2711_CR105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10096-004-1215-4","volume":"23","author":"L Ostrosky-Zeichner","year":"2004","unstructured":"Ostrosky-Zeichner L (2004) Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 23(10):739\u2013744","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"2711_CR106","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13693780410001731619","volume":"43","author":"NI Paphitou","year":"2005","unstructured":"Paphitou NI, Ostrosky-Zeichner L, Rex JH (2005) Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 43(3):235\u2013243","journal-title":"Med Mycol"},{"issue":"Suppl 6","key":"2711_CR107","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1086\/430923","volume":"41","author":"RP Wenzel","year":"2005","unstructured":"Wenzel RP, Gennings C (2005) Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 41(Suppl 6):S389\u2013S393","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2711_CR108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","volume":"65","author":"MJ Ruping","year":"2010","unstructured":"Ruping MJ et al (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65(2):296\u2013302","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2711_CR109","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","volume":"48","author":"D Neofytos","year":"2009","unstructured":"Neofytos D et al (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 48(3):265\u2013273","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2711_CR110","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","volume":"59","author":"OA Cornely","year":"2015","unstructured":"Cornely OA et al (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59(4):2078\u20132085","journal-title":"Antimicrob Agents Chemother"},{"key":"2711_CR111","doi-asserted-by":"publisher","unstructured":"Marty FM et al. (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case\u2013control analysis. Lancet Infect Dis. doi: 10.1016\/S1473-3099(16)00071-2","DOI":"10.1016\/S1473-3099(16)00071-2"},{"issue":"10020","key":"2711_CR112","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387(10020):760\u2013769","journal-title":"Lancet"},{"issue":"1","key":"2711_CR113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","volume":"93","author":"S Mousset","year":"2014","unstructured":"Mousset S et al (2014) Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93(1):13\u201332","journal-title":"Ann Hematol"},{"key":"2711_CR114","doi-asserted-by":"crossref","unstructured":"Wingard JR et al. (2010) Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood 116(24):5111\u20135118","DOI":"10.1182\/blood-2010-02-268151"},{"issue":"4","key":"2711_CR115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348\u2013359","journal-title":"N Engl J Med"},{"issue":"10","key":"2711_CR116","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","volume":"58","author":"RF Duarte","year":"2014","unstructured":"Duarte RF et al (2014) Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 58(10):5758\u20135765","journal-title":"Antimicrob Agents Chemother"},{"key":"2711_CR117","doi-asserted-by":"crossref","unstructured":"Cornely OA et al. (2016) Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 71(6):1747","DOI":"10.1093\/jac\/dkw079"},{"issue":"10","key":"2711_CR118","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","volume":"39","author":"JA Burik van","year":"2004","unstructured":"van Burik JA et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407\u20131416","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2711_CR119","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","volume":"103","author":"KA Marr","year":"2004","unstructured":"Marr KA et al (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103(4):1527\u20131533","journal-title":"Blood"},{"issue":"9","key":"2711_CR120","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/sj.leu.2401137","volume":"12","author":"A Glasmacher","year":"1998","unstructured":"Glasmacher A et al (1998) Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 12(9):1338\u20131343","journal-title":"Leukemia"},{"issue":"7\u20138","key":"2711_CR121","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","volume":"42","author":"A Glasmacher","year":"1999","unstructured":"Glasmacher A et al (1999) Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42(7\u20138):443\u2013451","journal-title":"Mycoses"},{"issue":"13","key":"2711_CR122","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","volume":"326","author":"JL Goodman","year":"1992","unstructured":"Goodman JL et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845\u2013851","journal-title":"N Engl J Med"},{"issue":"6","key":"2711_CR123","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","volume":"96","author":"KA Marr","year":"2000","unstructured":"Marr KA et al (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96(6):2055\u20132061","journal-title":"Blood"},{"issue":"6","key":"2711_CR124","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","volume":"171","author":"MA Slavin","year":"1995","unstructured":"Slavin MA et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study. J Infect Dis 171(6):1545\u20131552","journal-title":"J Infect Dis"},{"issue":"4","key":"2711_CR125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335\u2013347","journal-title":"N Engl J Med"},{"issue":"9","key":"2711_CR126","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704469","volume":"33","author":"C Cordonnier","year":"2004","unstructured":"Cordonnier C et al (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 33(9):943\u2013948","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2711_CR127","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bmt.1705720","volume":"40","author":"P Fabritiis de","year":"2007","unstructured":"de Fabritiis P et al (2007) Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and\/or systemic fungal infection. Bone Marrow Transplant 40(3):245\u2013249","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2711_CR128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1399-3062.2006.00189.x","volume":"9","author":"S Gupta","year":"2007","unstructured":"Gupta S et al (2007) Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 9(2):156\u2013160","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"2711_CR129","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","volume":"29","author":"JR Wingard","year":"1999","unstructured":"Wingard JR et al (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29(6):1402\u20131407","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2711_CR130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","volume":"32","author":"DW Bates","year":"2001","unstructured":"Bates DW et al (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32(5):686\u2013693","journal-title":"Clin Infect Dis"},{"key":"2711_CR131","doi-asserted-by":"crossref","unstructured":"Ullmann AJ et al (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 43(4):e29\u2013e38","DOI":"10.1086\/505969"},{"issue":"8","key":"2711_CR132","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","volume":"17","author":"O Penack","year":"2006","unstructured":"Penack O et al (2006) Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 17(8):1306\u20131312","journal-title":"Ann Oncol"},{"issue":"6","key":"2711_CR133","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01697981","volume":"71","author":"GF Behre","year":"1995","unstructured":"Behre GF et al (1995) Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 71(6):287\u2013291","journal-title":"Ann Hematol"},{"key":"2711_CR134","doi-asserted-by":"crossref","unstructured":"Luu Tran H et al. (2014) Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. J Oncol Pharm Pract 22(2):228\u2013234","DOI":"10.1177\/1078155214560920"},{"issue":"3","key":"2711_CR135","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/clpt.2010.261","volume":"89","author":"OA Cornely","year":"2011","unstructured":"Cornely OA, Ullmann AJ (2011) Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 89(3):351\u2013352","journal-title":"Clin Pharmacol Ther"},{"key":"2711_CR136","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijid.2013.09.020","volume":"19","author":"K Kawamura","year":"2014","unstructured":"Kawamura K et al (2014) Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. Int J Infect Dis 19:26\u201332","journal-title":"Int J Infect Dis"},{"issue":"3","key":"2711_CR137","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/infdis\/142.3.338","volume":"142","author":"JD Meyers","year":"1980","unstructured":"Meyers JD, Flournoy N, Thomas ED (1980) Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 142(3):338\u2013346","journal-title":"J Infect Dis"},{"issue":"2","key":"2711_CR138","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1056\/NEJM198107093050202","volume":"305","author":"R Saral","year":"1981","unstructured":"Saral R et al (1981) Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 305(2):63\u201367","journal-title":"N Engl J Med"},{"issue":"8352","key":"2711_CR139","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(83)92248-1","volume":"2","author":"E Gluckman","year":"1983","unstructured":"Gluckman E et al (1983) Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 2(8352):706\u2013708","journal-title":"Lancet"},{"issue":"3","key":"2711_CR140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7326\/0003-4819-96-3-265","volume":"96","author":"JC Wade","year":"1982","unstructured":"Wade JC et al (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 96(3):265\u2013269","journal-title":"Ann Intern Med"},{"issue":"6","key":"2711_CR141","doi-asserted-by":"crossref","first-page":"823","DOI":"10.7326\/0003-4819-100-6-823","volume":"100","author":"JC Wade","year":"1984","unstructured":"Wade JC et al (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100(6):823\u2013828","journal-title":"Ann Intern Med"},{"issue":"2","key":"2711_CR142","first-page":"185","volume":"1","author":"P Ljungman","year":"1986","unstructured":"Ljungman P et al (1986) Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1(2):185\u2013192","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2711_CR143","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3851\/IMP1870","volume":"16","author":"A Sauerbrei","year":"2011","unstructured":"Sauerbrei A et al (2011) Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther 16(8):1297\u20131308","journal-title":"Antivir Ther"},{"issue":"1A","key":"2711_CR144","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0002-9343(82)90126-7","volume":"73","author":"C McLaren","year":"1982","unstructured":"McLaren C, Sibrack CD, Barry DW (1982) Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates. Am J Med 73(1A):376\u2013379","journal-title":"Am J Med"},{"issue":"2","key":"2711_CR145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","volume":"55","author":"J Piret","year":"2011","unstructured":"Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55(2):459\u2013472","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2711_CR146","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archinte.1997.00440240109016","volume":"157","author":"GJ Mertz","year":"1997","unstructured":"Mertz GJ et al (1997) Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 157(3):343\u2013349","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"2711_CR147","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1086\/342966","volume":"186","author":"SK Tyring","year":"2002","unstructured":"Tyring SK, Baker D, Snowden W (2002) Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20\u00a0years\u2019 experience with acyclovir. J Infect Dis 186(Suppl 1):S40\u2013S46","journal-title":"J Infect Dis"},{"key":"2711_CR148","doi-asserted-by":"crossref","unstructured":"Garner JS (1996) Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hospital Epidemiol 17(1):53\u201380","DOI":"10.2307\/30142367"},{"issue":"1","key":"2711_CR149","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/infdis\/158.1.238","volume":"158","author":"A Josephson","year":"1988","unstructured":"Josephson A, Gombert ME (1988) Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 158(1):238\u2013241","journal-title":"J Infect Dis"},{"issue":"1","key":"2711_CR150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1083-8791(00)70051-6","volume":"6","author":"Y Koc","year":"2000","unstructured":"Koc Y et al (2000) Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 6(1):44\u201349","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2711_CR151","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1016\/j.vaccine.2011.02.067","volume":"29","author":"HC Rumke","year":"2011","unstructured":"Rumke HC et al (2011) Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine 29(22):3842\u20133849","journal-title":"Vaccine"},{"issue":"3","key":"2711_CR152","first-page":"277","volume":"13","author":"CS Han","year":"1994","unstructured":"Han CS et al (1994) Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 13(3):277\u2013283","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2711_CR153","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/infdis\/152.6.1172","volume":"152","author":"RM Locksley","year":"1985","unstructured":"Locksley RM et al (1985) Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 152(6):1172\u20131181","journal-title":"J Infect Dis"},{"issue":"10","key":"2711_CR154","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bbmt.2006.06.005","volume":"12","author":"DM Weinstock","year":"2006","unstructured":"Weinstock DM, Boeckh M, Sepkowitz KA (2006) Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12(10):1096\u20131097","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2711_CR155","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/infdis\/147.4.737","volume":"147","author":"JA Zaia","year":"1983","unstructured":"Zaia JA et al (1983) Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147(4):737\u2013743","journal-title":"J Infect Dis"},{"issue":"5","key":"2711_CR156","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","volume":"107","author":"M Boeckh","year":"2006","unstructured":"Boeckh M et al (2006) Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2014a randomized double-blind placebo-controlled study. Blood 107(5):1800\u20131805","journal-title":"Blood"},{"issue":"2","key":"2711_CR157","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/518938","volume":"196","author":"V Erard","year":"2007","unstructured":"Erard V et al (2007) Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 196(2):266\u2013270","journal-title":"J Infect Dis"},{"issue":"11","key":"2711_CR158","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.bmt.1704959","volume":"35","author":"KJ Thomson","year":"2005","unstructured":"Thomson KJ et al (2005) The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 35(11):1065\u20131069","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2711_CR159","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bmt.1703214","volume":"28","author":"Y Kanda","year":"2001","unstructured":"Kanda Y et al (2001) Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28(7):689\u2013692","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2711_CR160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","volume":"5","author":"C Gilbert","year":"2002","unstructured":"Gilbert C, Bestman-Smith J, Boivin G (2002) Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 5(2):88\u2013114","journal-title":"Drug Resist Updat"},{"issue":"4","key":"2711_CR161","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1046\/j.1365-2141.2001.02849.x","volume":"113","author":"N Kroger","year":"2001","unstructured":"Kroger N et al (2001) Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 113(4):1060\u20131071","journal-title":"Br J Haematol"},{"issue":"6","key":"2711_CR162","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","volume":"103","author":"M Boeckh","year":"2004","unstructured":"Boeckh M, Nichols WG (2004) The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103(6):2003\u20132008","journal-title":"Blood"},{"issue":"12","key":"2711_CR163","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1537-2995.2011.03203.x","volume":"51","author":"T Thiele","year":"2011","unstructured":"Thiele T et al (2011) Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 51(12):2620\u20132626","journal-title":"Transfusion"},{"issue":"6","key":"2711_CR164","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.bmt.1705090","volume":"36","author":"AB Narvios","year":"2005","unstructured":"Narvios AB et al (2005) Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplant 36(6):499\u2013501","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2711_CR165","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.bbmt.2013.09.013","volume":"19","author":"N Kekre","year":"2013","unstructured":"Kekre N et al (2013) Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant 19(12):1719\u20131724","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2711_CR166","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V78.1.246.246","volume":"78","author":"RA Bowden","year":"1991","unstructured":"Bowden RA et al (1991) Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78(1):246\u2013250","journal-title":"Blood"},{"issue":"9","key":"2711_CR167","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","volume":"86","author":"RA Bowden","year":"1995","unstructured":"Bowden RA et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86(9):3598\u20133603","journal-title":"Blood"},{"issue":"3","key":"2711_CR168","first-page":"227","volume":"7","author":"WJ Miller","year":"1991","unstructured":"Miller WJ et al (1991) Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 7(3):227\u2013234","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2711_CR169","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/00007890-199012000-00013","volume":"50","author":"T Witte De","year":"1990","unstructured":"De Witte T et al (1990) Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50(6):964\u2013968","journal-title":"Transplantation"},{"issue":"7","key":"2711_CR170","first-page":"749","volume":"86","author":"AB Narvios","year":"2001","unstructured":"Narvios AB, Lichtiger B (2001) Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Haematologica 86(7):749\u2013752","journal-title":"Haematologica"},{"issue":"3","key":"2711_CR171","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1086\/517301","volume":"176","author":"JA Zaia","year":"1997","unstructured":"Zaia JA et al (1997) Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 176(3):782\u2013785","journal-title":"J Infect Dis"},{"issue":"3\u20134","key":"2711_CR172","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF02999860","volume":"11","author":"A Nagler","year":"1994","unstructured":"Nagler A et al (1994) Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation. Med Oncol 11(3\u20134):127\u2013132","journal-title":"Med Oncol"},{"issue":"5","key":"2711_CR173","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12185-010-0597-6","volume":"91","author":"M Schmidt-Hieber","year":"2010","unstructured":"Schmidt-Hieber M et al (2010) Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 91(5):877\u2013885","journal-title":"Int J Hematol"},{"issue":"8776","key":"2711_CR174","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/0140-6736(91)92032-W","volume":"338","author":"H Einsele","year":"1991","unstructured":"Einsele H et al (1991) Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 338(8776):1170\u20131172","journal-title":"Lancet"},{"issue":"7","key":"2711_CR175","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V83.7.1971.1971","volume":"83","author":"CR Li","year":"1994","unstructured":"Li CR et al (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83(7):1971\u20131979","journal-title":"Blood"},{"issue":"4","key":"2711_CR176","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","volume":"111","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S et al (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816\u20131819","journal-title":"Blood"},{"issue":"1","key":"2711_CR177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","volume":"162","author":"M Boeckh","year":"2015","unstructured":"Boeckh M et al (2015) Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 162(1):1\u201310","journal-title":"Ann Intern Med"},{"issue":"3","key":"2711_CR178","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bmt.1700649","volume":"19","author":"T Ruutu","year":"1997","unstructured":"Ruutu T et al (1997) No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. the Nordic BMT Group. Bone Marrow Transplant 19(3):233\u2013236","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2711_CR179","first-page":"132","volume":"83","author":"P Zikos","year":"1998","unstructured":"Zikos P et al (1998) A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83(2):132\u2013137","journal-title":"Haematologica"},{"issue":"2","key":"2711_CR180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198801143180202","volume":"318","author":"JD Meyers","year":"1988","unstructured":"Meyers JD et al (1988) Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318(2):70\u201375","journal-title":"N Engl J Med"},{"issue":"6","key":"2711_CR181","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","volume":"36","author":"DJ Winston","year":"2003","unstructured":"Winston DJ et al (2003) Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 36(6):749\u2013758","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2711_CR182","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","volume":"99","author":"P Ljungman","year":"2002","unstructured":"Ljungman P et al (2002) Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99(8):3050\u20133056","journal-title":"Blood"},{"issue":"3","key":"2711_CR183","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.bmt.1703129","volume":"28","author":"M Vusirikala","year":"2001","unstructured":"Vusirikala M et al (2001) Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 28(3):265\u2013270","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2711_CR184","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/infdis\/172.4.939","volume":"172","author":"M Boeckh","year":"1995","unstructured":"Boeckh M et al (1995) Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 172(4):939\u2013943","journal-title":"J Infect Dis"},{"issue":"11","key":"2711_CR185","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","volume":"111","author":"DJ Winston","year":"2008","unstructured":"Winston DJ et al (2008) Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111(11):5403\u20135410","journal-title":"Blood"},{"key":"2711_CR186","doi-asserted-by":"crossref","unstructured":"Avery RK et al (2010) Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transplant Infect Dis 12(6):489\u2013496","DOI":"10.1111\/j.1399-3062.2010.00550.x"},{"issue":"4","key":"2711_CR187","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","volume":"11","author":"FM Marty","year":"2011","unstructured":"Marty FM et al (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11(4):284\u2013292","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"2711_CR188","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","volume":"369","author":"FM Marty","year":"2013","unstructured":"Marty FM et al (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369(13):1227\u20131236","journal-title":"N Engl J Med"},{"issue":"19","key":"2711_CR189","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","volume":"370","author":"RF Chemaly","year":"2014","unstructured":"Chemaly RF et al (2014) Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370(19):1781\u20131789","journal-title":"N Engl J Med"},{"issue":"4","key":"2711_CR190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","volume":"12","author":"MA Kharfan-Dabaja","year":"2012","unstructured":"Kharfan-Dabaja MA et al (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12(4):290\u2013299","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"2711_CR191","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis RE et al (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94(7):2208\u20132216","journal-title":"Blood"},{"issue":"12","key":"2711_CR192","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bbmt.2009.08.002","volume":"15","author":"H Bertz","year":"2009","unstructured":"Bertz H et al (2009) A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 15(12):1563\u20131570","journal-title":"Biol Blood Marrow Transplant"},{"key":"2711_CR193","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-642-56352-2_11","volume":"159","author":"SH Oertel","year":"2002","unstructured":"Oertel SH, Riess H (2002) Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res 159:89\u201395","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"2711_CR194","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1399-0012.1995.tb00297.x","volume":"9","author":"CL Davis","year":"1995","unstructured":"Davis CL et al (1995) Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 9(1):53\u201359","journal-title":"Clin Transplant"},{"issue":"7","key":"2711_CR195","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.23452","volume":"88","author":"Q Liu","year":"2013","unstructured":"Liu Q et al (2013) Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 88(7):550\u2013555","journal-title":"Am J Hematol"},{"issue":"3","key":"2711_CR196","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jmv.21096","volume":"80","author":"A Meerbach","year":"2008","unstructured":"Meerbach A et al (2008) Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 80(3):441\u2013454","journal-title":"J Med Virol"},{"issue":"11","key":"2711_CR197","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/sj.bmt.1704061","volume":"31","author":"B Gruhn","year":"2003","unstructured":"Gruhn B et al (2003) Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 31(11):1023\u20131025","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2711_CR198","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","volume":"92","author":"CM Rooney","year":"1998","unstructured":"Rooney CM et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549\u20131555","journal-title":"Blood"},{"issue":"8","key":"2711_CR199","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","volume":"20","author":"U Gerdemann","year":"2012","unstructured":"Gerdemann U et al (2012) Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20(8):1622\u20131632","journal-title":"Mol Ther"},{"issue":"3","key":"2711_CR200","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.actatropica.2013.05.006","volume":"127","author":"J Yan","year":"2013","unstructured":"Yan J et al (2013) Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. Acta Trop 127(3):236\u2013244","journal-title":"Acta Trop"},{"issue":"8739","key":"2711_CR201","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0140-6736(91)93402-U","volume":"337","author":"J Ruskin","year":"1991","unstructured":"Ruskin J, LaRiviere M (1991) Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 337(8739):468\u2013471","journal-title":"Lancet"},{"issue":"3","key":"2711_CR202","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1034\/j.1399-3062.2000.020305.x","volume":"2","author":"S Bretagne","year":"2000","unstructured":"Bretagne S et al (2000) Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients. Transpl Infect Dis 2(3):127\u2013132","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"2711_CR203","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.bmt.1703175","volume":"28","author":"JM Costa","year":"2001","unstructured":"Costa JM et al (2001) Quality control for the diagnosis of Toxoplasma gondii reactivation in SCT patients using PCR assays. Bone Marrow Transplant 28(5):527\u2013528","journal-title":"Bone Marrow Transplant"},{"key":"2711_CR204","doi-asserted-by":"crossref","unstructured":"Katlama C et al (1996) Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 22(2):268\u2013275","DOI":"10.1093\/clinids\/22.2.268"},{"issue":"3","key":"2711_CR205","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-123-3-199508010-00003","volume":"123","author":"D Podzamczer","year":"1995","unstructured":"Podzamczer D et al (1995) Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. Ann Intern Med 123(3):175\u2013180","journal-title":"Ann Intern Med"},{"issue":"10","key":"2711_CR206","first-page":"1107","volume":"10","author":"C Katlama","year":"1996","unstructured":"Katlama C et al (1996) Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expand Access Group AIDS 10(10):1107\u20131112","journal-title":"Atovaquone Expand Access Group AIDS"},{"key":"2711_CR207","doi-asserted-by":"crossref","unstructured":"Garcia Garrido HM et al. (2015) Response to hepatitis A vaccination in immunocompromised travelers. J Infect Dis 212(3):378\u2013385","DOI":"10.1093\/infdis\/jiv060"},{"issue":"3","key":"2711_CR208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62(3):299\u2013307","journal-title":"J Med Virol"},{"issue":"12","key":"2711_CR209","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jmv.20705","volume":"78","author":"SE Moses","year":"2006","unstructured":"Moses SE et al (2006) Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 78(12):1560\u20131563","journal-title":"J Med Virol"},{"issue":"4","key":"2711_CR210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1703826","volume":"31","author":"A Locasciulli","year":"2003","unstructured":"Locasciulli A et al (2003) Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)\/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31(4):295\u2013300","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2711_CR211","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2893.2006.00830.x","volume":"14","author":"A Knoll","year":"2007","unstructured":"Knoll A et al (2007) Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 14(7):478\u2013483","journal-title":"J Viral Hepat"},{"issue":"6","key":"2711_CR212","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cgh.2013.10.034","volume":"12","author":"P Mahale","year":"2014","unstructured":"Mahale P, Okhuysen PC, Torres HA (2014) Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? Clin Gastroenterol Hepatol 12(6):1051\u20131054, e1","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"2711_CR213","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang TJ, Ghany MG (2014) Therapy of hepatitis C\u2014back to the future. N Engl J Med 370(21):2043\u20132047","journal-title":"N Engl J Med"},{"key":"2711_CR214","unstructured":"(2013) A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24\u201328, 2013 * Amsterdam, The NetherlandsSpecial Reporting on:* Simeprevir Plus Peginterferon\/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection* Addition of Simeprevir to Peginterferon\/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients* Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2\/3 Populations* Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir* Addition of TG4040 Vaccine to Peginterferon\/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York. Gastroenterol Hepatol (N Y) 9(6 Suppl 3): 1\u201318"},{"issue":"1","key":"2711_CR215","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/01.TP.0000072012.26176.58","volume":"76","author":"SM Raboni","year":"2003","unstructured":"Raboni SM et al (2003) Respiratory tract viral infections in bone marrow transplant patients. Transplantation 76(1):142\u2013146","journal-title":"Transplantation"},{"issue":"11","key":"2711_CR216","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/sj.bmt.1704257","volume":"32","author":"M Roghmann","year":"2003","unstructured":"Roghmann M et al (2003) Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 32(11):1085\u20131088","journal-title":"Bone Marrow Transplant"},{"key":"2711_CR217","doi-asserted-by":"crossref","unstructured":"Sullivan KM et al. (2001) Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematol Am Soc Hematol Educ Program 392\u2013421","DOI":"10.1182\/asheducation-2001.1.392"},{"issue":"12","key":"2711_CR218","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/bmt.2013.94","volume":"48","author":"N Lehners","year":"2013","unstructured":"Lehners N et al (2013) Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant 48(12):1548\u20131553","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2711_CR219","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1017\/ice.2015.150","volume":"36","author":"EJ Ariza-Heredia","year":"2015","unstructured":"Ariza-Heredia EJ et al (2015) Influenza vaccination in patients with cancer: factors associated with vaccination practices for patients and their household members. Infect Control Hosp Epidemiol 36(10):1239\u20131241","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2711_CR220","doi-asserted-by":"crossref","unstructured":"Dykewicz CA (2001) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant 7(Suppl):19S\u201322S","DOI":"10.1053\/bbmt.2001.v7.pm11777100"},{"issue":"6","key":"2711_CR221","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1086\/342412","volume":"186","author":"K Cortez","year":"2002","unstructured":"Cortez K et al (2002) Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis 186(6):834\u2013838","journal-title":"J Infect Dis"},{"issue":"2 Suppl 1","key":"2711_CR222","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.tmrv.2007.01.004","volume":"21","author":"P Robinson","year":"2007","unstructured":"Robinson P et al (2007) Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 21(2 Suppl 1):S3\u2013S8","journal-title":"Transfus Med Rev"},{"issue":"11","key":"2711_CR223","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJM199009133231103","volume":"323","author":"KM Sullivan","year":"1990","unstructured":"Sullivan KM et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323(11):705\u2013712","journal-title":"N Engl J Med"},{"issue":"1","key":"2711_CR224","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-106-1-12","volume":"106","author":"DJ Winston","year":"1987","unstructured":"Winston DJ et al (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106(1):12\u201318","journal-title":"Ann Intern Med"},{"issue":"5","key":"2711_CR225","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","volume":"27","author":"P Raanani","year":"2009","unstructured":"Raanani P et al (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol : Off J Am Soc Clin Oncol 27(5):770\u2013781","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"2711_CR226","first-page":"CD006501","volume":"4","author":"P Raanani","year":"2008","unstructured":"Raanani P et al (2008) Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 4:CD006501","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2711_CR227","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-139-1-200307010-00007","volume":"139","author":"C Cordonnier","year":"2003","unstructured":"Cordonnier C et al (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139(1):8\u201318","journal-title":"Ann Intern Med"},{"issue":"3","key":"2711_CR228","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/bmt.2008.435","volume":"44","author":"M Schmidt-Hieber","year":"2009","unstructured":"Schmidt-Hieber M et al (2009) Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT. Bone Marrow Transplant 44(3):185\u2013192","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2711_CR229","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","volume":"41","author":"AC Norlin","year":"2008","unstructured":"Norlin AC et al (2008) Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 41(3):267\u2013273","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2711_CR230","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/0003-4819-118-9-199305010-00011","volume":"118","author":"MC Sneller","year":"1993","unstructured":"Sneller MC et al (1993) NIH conference. New insights into common variable immunodeficiency. Ann Intern Med 118(9):720\u2013730","journal-title":"Ann Intern Med"},{"issue":"1","key":"2711_CR231","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1365-2141.2003.04583.x","volume":"123","author":"JP Kerr","year":"2003","unstructured":"Kerr JP et al (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 123(1):114\u2013118","journal-title":"Br J Haematol"},{"issue":"1","key":"2711_CR232","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1537-2995.2005.00665.x","volume":"46","author":"A Oza","year":"2006","unstructured":"Oza A et al (2006) Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion 46(1):14\u201323","journal-title":"Transfusion"},{"key":"2711_CR233","unstructured":"EMA (2006) E.M.A., Guideline on clinical evaluation of new vaccines. EMEA\/CHMP\/VWP\/164653\/2005"},{"issue":"3","key":"2711_CR234","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bmt.1703354","volume":"29","author":"MC Dignani","year":"2002","unstructured":"Dignani MC et al (2002) Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant 29(3):263\u2013267","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2711_CR235","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1399-0012.2008.00877.x","volume":"22","author":"DH Kim","year":"2008","unstructured":"Kim DH et al (2008) Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 22(6):770\u2013779","journal-title":"Clin Transplant"},{"issue":"8","key":"2711_CR236","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2007-03-077644","volume":"110","author":"V Erard","year":"2007","unstructured":"Erard V et al (2007) One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110(8):3071\u20133077","journal-title":"Blood"},{"key":"2711_CR237","doi-asserted-by":"crossref","unstructured":"Oshima K, et al. (2010) One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis 12(5):421-427","DOI":"10.1111\/j.1399-3062.2010.00541.x"},{"issue":"6","key":"2711_CR238","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21152","volume":"83","author":"Y Asano-Mori","year":"2008","unstructured":"Asano-Mori Y et al (2008) Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 83(6):472\u2013476","journal-title":"Am J Hematol"},{"issue":"7","key":"2711_CR239","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood.V86.7.2815.2815","volume":"86","author":"H Einsele","year":"1995","unstructured":"Einsele H et al (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86(7):2815\u20132820","journal-title":"Blood"},{"issue":"4","key":"2711_CR240","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","volume":"99","author":"P Reusser","year":"2002","unstructured":"Reusser P et al (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99(4):1159\u20131164","journal-title":"Blood"},{"issue":"7","key":"2711_CR241","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2005-09-3786","volume":"107","author":"H Einsele","year":"2006","unstructured":"Einsele H et al (2006) Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107(7):3002\u20133008","journal-title":"Blood"},{"issue":"9","key":"2711_CR242","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bmt.1705341","volume":"37","author":"E Ayala","year":"2006","unstructured":"Ayala E et al (2006) Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37(9):851\u2013856","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2711_CR243","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bmt.1703770","volume":"30","author":"LJ Burns","year":"2002","unstructured":"Burns LJ et al (2002) Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 30(12):945\u2013951","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2711_CR244","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/clinids\/24.5.901","volume":"24","author":"LF Verdonck","year":"1997","unstructured":"Verdonck LF et al (1997) A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 24(5):901\u2013907","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2711_CR245","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","volume":"13","author":"K Micklethwaite","year":"2007","unstructured":"Micklethwaite K et al (2007) Ex vivo expansion and prophylactic infusion of CMV-pp 65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13(6):707\u2013714","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2711_CR246","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","volume":"36","author":"GK Lau","year":"2002","unstructured":"Lau GK et al (2002) Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36(3):702\u2013709","journal-title":"Hepatology"},{"issue":"7","key":"2711_CR247","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519\u2013528","journal-title":"Ann Intern Med"},{"issue":"10","key":"2711_CR248","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001\u20131010","journal-title":"N Engl J Med"},{"issue":"9","key":"2711_CR249","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/jgh.12604","volume":"29","author":"A Tamori","year":"2014","unstructured":"Tamori A et al (2014) Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol 29(9):1715\u20131721","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2711_CR250","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2015.328","volume":"51","author":"J Shang","year":"2016","unstructured":"Shang J et al (2016) A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience. Bone Marrow Transplant 51(4):581\u2013586","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2711_CR251","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ejim.2014.06.028","volume":"25","author":"JS Koskinas","year":"2014","unstructured":"Koskinas JS et al (2014) The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. a real life experience from a tertiary center. Eur J Intern Med 25(8):768\u2013771","journal-title":"Eur J Intern Med"},{"issue":"12","key":"2711_CR252","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/hepr.12249","volume":"44","author":"J Leong","year":"2014","unstructured":"Leong J et al (2014) Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts. Hepatol Res 44(12):1248\u20131252","journal-title":"Hepatol Res"},{"issue":"3","key":"2711_CR253","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1034\/j.1600-0609.2003.00114.x","volume":"71","author":"T Chiba","year":"2003","unstructured":"Chiba T et al (2003) Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. Eur J Haematol 71(3):220\u2013223","journal-title":"Eur J Haematol"},{"issue":"4","key":"2711_CR254","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-0609.2009.01291.x","volume":"83","author":"K Matsue","year":"2009","unstructured":"Matsue K et al (2009) High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 83(4):357\u2013364","journal-title":"Eur J Haematol"},{"issue":"3","key":"2711_CR255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01964458","volume":"10","author":"CU Foppa","year":"1991","unstructured":"Foppa CU et al (1991) A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. Eur J Clin Microbiol Infect Dis 10(3):187\u2013189","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"2711_CR256","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01964459","volume":"10","author":"C Katlama","year":"1991","unstructured":"Katlama C (1991) Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur J Clin Microbiol Infect Dis 10(3):189\u2013191","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"2711_CR257","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/160.3.557","volume":"160","author":"C Leport","year":"1989","unstructured":"Leport C et al (1989) An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis. J Infect Dis 160(3):557\u2013558","journal-title":"J Infect Dis"},{"issue":"10","key":"2711_CR258","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1086\/598324","volume":"48","author":"C Cordonnier","year":"2009","unstructured":"Cordonnier C et al (2009) Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 48(10):1392\u20131401","journal-title":"Clin Infect Dis"},{"issue":"19","key":"2711_CR259","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","volume":"115","author":"R Seggewiss","year":"2010","unstructured":"Seggewiss R, Einsele H (2010) Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 115(19):3861\u20133868","journal-title":"Blood"},{"issue":"2","key":"2711_CR260","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","volume":"33","author":"RA Eisenberg","year":"2013","unstructured":"Eisenberg RA et al (2013) Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33(2):388\u2013396","journal-title":"J Clin Immunol"},{"issue":"10","key":"2711_CR261","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.4049\/jimmunol.1004095","volume":"186","author":"D Bedognetti","year":"2011","unstructured":"Bedognetti D et al (2011) Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing regimens. J Immunol 186(10):6044\u20136055","journal-title":"J Immunol"},{"issue":"9","key":"2711_CR262","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3109\/0284186X.2014.914243","volume":"53","author":"A Berglund","year":"2014","unstructured":"Berglund A et al (2014) The response to vaccination against influenza A (H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 53(9):1212\u20131220","journal-title":"Acta Oncol"},{"key":"2711_CR263","doi-asserted-by":"crossref","unstructured":"Juergens C et al. (2014) Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: A randomized open-label trial. Hum Vaccin Immunother 10(5)","DOI":"10.4161\/hv.27998"},{"issue":"1","key":"2711_CR264","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","volume":"347","author":"A Hata","year":"2002","unstructured":"Hata A et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347(1):26\u201334","journal-title":"N Engl J Med"},{"issue":"7","key":"2711_CR265","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/eji.1830270720","volume":"27","author":"SR Burrows","year":"1997","unstructured":"Burrows SR et al (1997) Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 27(7):1726\u20131736","journal-title":"Eur J Immunol"},{"issue":"5","key":"2711_CR266","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.vaccine.2013.11.073","volume":"32","author":"N Dhedin","year":"2014","unstructured":"Dhedin N et al (2014) Comparable humoral response after two doses of adjuvanted influenza A\/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine 32(5):585\u2013591","journal-title":"Vaccine"},{"issue":"8","key":"2711_CR267","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1111\/j.1651-2227.2012.02710.x","volume":"101","author":"H Olkinuora","year":"2012","unstructured":"Olkinuora H et al (2012) Immunity after (re) vaccination of paediatric patients following haematopoietic stem cell transplantation. Acta Paediatr 101(8):e373\u2013e377","journal-title":"Acta Paediatr"},{"issue":"16","key":"2711_CR268","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.vaccine.2011.02.018","volume":"29","author":"I Hilgendorf","year":"2011","unstructured":"Hilgendorf I et al (2011) Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine 29(16):2825\u20132833","journal-title":"Vaccine"},{"issue":"9","key":"2711_CR269","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2008.06.012","volume":"14","author":"M Pao","year":"2008","unstructured":"Pao M et al (2008) Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 14(9):1022\u20131030","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2711_CR270","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.vaccine.2010.01.025","volume":"28","author":"C Cordonnier","year":"2010","unstructured":"Cordonnier C et al (2010) Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 28(15):2730\u20132734","journal-title":"Vaccine"},{"issue":"2","key":"2711_CR271","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/TP.0b013e3181772a75","volume":"86","author":"G Avetisyan","year":"2008","unstructured":"Avetisyan G et al (2008) Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 86(2):257\u2013263","journal-title":"Transplantation"},{"issue":"10","key":"2711_CR272","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/bmt.2008.264","volume":"42","author":"P Ljungman","year":"2008","unstructured":"Ljungman P, Avetisyan G (2008) Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 42(10):637\u2013641","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2711_CR273","first-page":"1","volume":"11","author":"D Engelhard","year":"1993","unstructured":"Engelhard D et al (1993) Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 11(1):1\u20135","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2711_CR274","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2011.02.004","volume":"17","author":"S Gueller","year":"2011","unstructured":"Gueller S et al (2011) Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17(10):1546\u20131550","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2711_CR275","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2010.032664","volume":"96","author":"H Lavallade de","year":"2011","unstructured":"de Lavallade H et al (2011) Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 96(2):307\u2013314","journal-title":"Haematologica"},{"issue":"1","key":"2711_CR276","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2011.08913.x","volume":"156","author":"H Inaba","year":"2012","unstructured":"Inaba H et al (2012) Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol 156(1):109\u2013117","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"2711_CR277","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/infdis\/jit592","volume":"209","author":"LC Lambert","year":"2014","unstructured":"Lambert LC (2014) Pertussis vaccine trials in the 1990s. J Infect Dis 209(Suppl 1):S4\u2013S9","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2711_CR278","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/infdis\/jit560","volume":"209","author":"KM Edwards","year":"2014","unstructured":"Edwards KM, Berbers GA (2014) Immune responses to pertussis vaccines and disease. J Infect Dis 209(Suppl 1):S10\u2013S15","journal-title":"J Infect Dis"},{"issue":"9","key":"2711_CR279","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bmt.1700768","volume":"19","author":"T Parkkali","year":"1997","unstructured":"Parkkali T et al (1997) A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant 19(9):933\u2013938","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2711_CR280","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/infdis\/162.2.496","volume":"162","author":"P Ljungman","year":"1990","unstructured":"Ljungman P et al (1990) Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 162(2):496\u2013500","journal-title":"J Infect Dis"},{"issue":"2","key":"2711_CR281","first-page":"225","volume":"14","author":"S Li Volti","year":"1994","unstructured":"Li Volti S et al (1994) Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow-transplanted thalassemic patients. Bone Marrow Transplant 14(2):225\u2013227","journal-title":"Bone Marrow Transplant"},{"issue":"7\u20138","key":"2711_CR282","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0264-410X(98)00272-2","volume":"17","author":"TJ Dengler","year":"1999","unstructured":"Dengler TJ et al (1999) Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine 17(7\u20138):867\u2013874","journal-title":"Vaccine"},{"issue":"2","key":"2711_CR283","first-page":"89","volume":"7","author":"P Ljungman","year":"1991","unstructured":"Ljungman P, Duraj V, Magnius L (1991) Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 7(2):89\u201393","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2711_CR284","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1699-0463.1996.tb00731.x","volume":"104","author":"T Parkkali","year":"1996","unstructured":"Parkkali T et al (1996) Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation. APMIS 104(5):383\u2013388","journal-title":"APMIS"},{"issue":"4","key":"2711_CR285","first-page":"295","volume":"8","author":"D Engelhard","year":"1991","unstructured":"Engelhard D et al (1991) Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 8(4):295\u2013300","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2711_CR286","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.bmt.1700959","volume":"20","author":"T Parkkali","year":"1997","unstructured":"Parkkali T et al (1997) Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant 20(8):663\u2013668","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2711_CR287","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.bmt.1704678","volume":"34","author":"P Ljungman","year":"2004","unstructured":"Ljungman P et al (2004) Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 34(12):1067\u20131069","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2711_CR288","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bmt.1705562","volume":"39","author":"T Parkkali","year":"2007","unstructured":"Parkkali T et al (2007) A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant 39(3):179\u2013188","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2711_CR289","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/infdis\/166.5.1021","volume":"166","author":"A Barra","year":"1992","unstructured":"Barra A et al (1992) Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 166(5):1021\u20131028","journal-title":"J Infect Dis"},{"issue":"5","key":"2711_CR290","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00007890-199403150-00009","volume":"57","author":"EC Guinan","year":"1994","unstructured":"Guinan EC et al (1994) Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 57(5):677\u2013684","journal-title":"Transplantation"},{"issue":"5","key":"2711_CR291","first-page":"961","volume":"18","author":"T Parkkali","year":"1996","unstructured":"Parkkali T et al (1996) A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 18(5):961\u2013967","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2711_CR292","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.bmt.1701424","volume":"22","author":"E Vance","year":"1998","unstructured":"Vance E et al (1998) Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 22(8):735\u2013741","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2711_CR293","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cir268","volume":"53","author":"K Wessel van","year":"2011","unstructured":"van Wessel K et al (2011) Nontypeable Haemophilus influenzae invasive disease in The Netherlands: a retrospective surveillance study 2001\u20132008. Clin Infect Dis 53(1):e1\u2013e7","journal-title":"Clin Infect Dis"},{"key":"2711_CR294","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2334-9-45","volume":"9","author":"H Kalies","year":"2009","unstructured":"Kalies H et al (2009) Invasive Haemophilus influenzae infections in Germany: impact of non-type b serotypes in the post-vaccine era. BMC Infect Dis 9:45","journal-title":"BMC Infect Dis"},{"issue":"5","key":"2711_CR295","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/511641","volume":"44","author":"SR Patel","year":"2007","unstructured":"Patel SR et al (2007) Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 44(5):625\u2013634","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2711_CR296","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/00365540802029565","volume":"40","author":"S Jacobsson","year":"2008","unstructured":"Jacobsson S et al (2008) Characteristics of Neisseria meningitidis isolates causing fatal disease. Scand J Infect Dis 40(9):734\u2013744","journal-title":"Scand J Infect Dis"},{"issue":"8506","key":"2711_CR297","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(86)90123-6","volume":"2","author":"JT Poolman","year":"1986","unstructured":"Poolman JT et al (1986) Meningococcal serotypes and serogroup B disease in north-west Europe. Lancet 2(8506):555\u2013558","journal-title":"Lancet"},{"issue":"11","key":"2711_CR298","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.bbmt.2008.08.007","volume":"14","author":"M Onozawa","year":"2008","unstructured":"Onozawa M et al (2008) HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 14(11):1226\u20131230","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2711_CR299","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2006-04-006981","volume":"108","author":"D Jaffe","year":"2006","unstructured":"Jaffe D et al (2006) Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 108(7):2470\u20132475","journal-title":"Blood"},{"issue":"5","key":"2711_CR300","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1034\/j.1399-0012.2003.00070.x","volume":"17","author":"R Idilman","year":"2003","unstructured":"Idilman R et al (2003) Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin Transplant 17(5):438\u2013443","journal-title":"Clin Transplant"},{"issue":"4","key":"2711_CR301","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/159.4.610","volume":"159","author":"P Ljungman","year":"1989","unstructured":"Ljungman P et al (1989) Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 159(4):610\u2013615","journal-title":"J Infect Dis"},{"issue":"12","key":"2711_CR302","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.bmt.1704476","volume":"33","author":"V Spoulou","year":"2004","unstructured":"Spoulou V et al (2004) Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 33(12):1187\u20131190","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2711_CR303","first-page":"633","volume":"17","author":"SM King","year":"1996","unstructured":"King SM et al (1996) Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 17(4):633\u2013636","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2711_CR304","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1700909","volume":"20","author":"A Sauerbrei","year":"1997","unstructured":"Sauerbrei A et al (1997) Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 20(5):381\u2013383","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2711_CR305","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbmt.2013.11.013","volume":"20","author":"NC Issa","year":"2014","unstructured":"Issa NC et al (2014) Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 20(2):285\u2013287","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2711_CR306","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/bmt.2010.31","volume":"45","author":"SC Kussmaul","year":"2010","unstructured":"Kussmaul SC et al (2010) Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant 45(11):1602\u20131606","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2711_CR307","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bbmt.2015.12.025","volume":"22","author":"T Aoki","year":"2016","unstructured":"Aoki T et al (2016) Safety of live attenuated high-titer varicella-zoster virus vaccine in pediatric allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 22(4):771\u2013775","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2711_CR308","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cid\/civ287","volume":"61","author":"C Cordonnier","year":"2015","unstructured":"Cordonnier C et al (2015) Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >\/=2\u00a0years: an open-label study. Clin Infect Dis 61(3):313\u2013323","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2711_CR309","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/00006454-199809000-00011","volume":"17","author":"PC Begue","year":"1998","unstructured":"Begue PC et al (1998) Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents. Pediatr Infect Dis J 17(9):804\u2013809","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2711_CR310","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.bbmt.2009.07.020","volume":"15","author":"A Meerveld-Eggink","year":"2009","unstructured":"Meerveld-Eggink A et al (2009) Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 15(12):1523\u20131530","journal-title":"Biol Blood Marrow Transplant"},{"key":"2711_CR311","doi-asserted-by":"crossref","unstructured":"Townsend K et al. (2014) Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection. Vaccine 32(43):5650\u20135656","DOI":"10.1016\/j.vaccine.2014.08.010"},{"issue":"4","key":"2711_CR312","first-page":"332","volume":"11","author":"JB Pinson","year":"1992","unstructured":"Pinson JB, Weart CW (1992) New considerations for Haemophilus influenzae type b vaccination. Clin Pharm 11(4):332\u2013336","journal-title":"Clin Pharm"},{"issue":"30","key":"2711_CR313","first-page":"1018","volume":"60","author":"Centers for Disease, C. and Prevention","year":"2011","unstructured":"Centers for Disease, C. and Prevention (2011) Licensure of a meningococcal conjugate vaccine for children aged 2 through 10\u00a0years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 60(30):1018\u20131019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"2711_CR314","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4161\/hv.7.7.15997","volume":"7","author":"D Toneatto","year":"2011","unstructured":"Toneatto D et al (2011) Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 7(7):781\u2013791","journal-title":"Hum Vaccin"},{"issue":"1","key":"2711_CR315","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbmt.2011.07.027","volume":"18","author":"MB Mahler","year":"2012","unstructured":"Mahler MB et al (2012) Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(1):145\u2013149","journal-title":"Biol Blood Marrow Transplant"},{"issue":"34","key":"2711_CR316","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.vaccine.2014.06.028","volume":"32","author":"J Beran","year":"2014","unstructured":"Beran J, Xie F, Zent O (2014) Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety. Vaccine 32(34):4275\u20134280","journal-title":"Vaccine"},{"issue":"9","key":"2711_CR317","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1086\/606119","volume":"200","author":"BJ McMahon","year":"2009","unstructured":"McMahon BJ et al (2009) Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 200(9):1390\u20131396","journal-title":"J Infect Dis"},{"issue":"4","key":"2711_CR318","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2010.04.015","volume":"56","author":"J Tung","year":"2010","unstructured":"Tung J et al (2010) A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis 56(4):713\u2013719","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2711_CR319","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1258\/ijsa.2009.009126","volume":"20","author":"HN Kim","year":"2009","unstructured":"Kim HN et al (2009) Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 20(9):595\u2013600","journal-title":"Int J STD AIDS"},{"issue":"2","key":"2711_CR320","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bmt.1700635","volume":"19","author":"S Li Volti","year":"1997","unstructured":"Li Volti S et al (1997) Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 19(2):157\u2013160","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2711_CR321","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/140349488801600301","volume":"16","author":"K Fahlgren","year":"1988","unstructured":"Fahlgren K (1988) Two doses of MMR vaccine--sufficient to eradicate measles, mumps and rubella? Scand J Soc Med 16(3):129\u2013135","journal-title":"Scand J Soc Med"},{"issue":"3","key":"2711_CR322","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1542\/peds.99.3.479","volume":"99","author":"American Academy of Pediatrics Committee on Infectious Diseases","year":"1997","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases (1997) Immunization of adolescents: recommendations of the advisory committee on immunization practices, the american academy of pediatrics, the american academy of family physicians, and the american medical association. Pediatrics 99(3):479\u2013488","journal-title":"Pediatrics"},{"issue":"1","key":"2711_CR323","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/171.1.13","volume":"171","author":"S Nader","year":"1995","unstructured":"Nader S et al (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171(1):13\u201317","journal-title":"J Infect Dis"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2711-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2711-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2711-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T18:44:25Z","timestamp":1748976265000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2711-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":323,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2711-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,24]]}}}